PMID- 24378597
OWN - NLM
STAT- MEDLINE
DCOM- 20150106
LR  - 20180913
IS  - 1536-4844 (Electronic)
IS  - 1078-0998 (Linking)
VI  - 20
IP  - 2
DP  - 2014 Feb
TI  - T-cell profiling and the immunodiagnosis of latent tuberculosis infection in 
      patients with inflammatory bowel disease.
PG  - 329-38
LID - 10.1097/01.MIB.0000438429.38423.62 [doi]
AB  - BACKGROUND: Factors associated with performance of interferon-gamma release assays 
      (IGRA) and the tuberculin skin test (TST) in screening for latent tuberculosis 
      infection in patients with inflammatory bowel diseases (IBD) are still poorly 
      understood. The influence of peripheral T-cell subset counts on the results also 
      remain unclear. METHODS: Prospective single-center study in 205 patients with 
      IBD. Latent tuberculosis infection screening included a chest radiograph, TST 
      (retest if negative), and 2 IGRAs: QuantiFERON-TB Gold In-Tube (QFT-GIT) and 
      TSPOT-TB (TSPOT). T-cell subpopulations were determined by flow cytometry. 
      RESULTS: Twenty-one (10.2%) patients had an abnormal chest radiograph, 55 (26.8%) 
      had a positive TST, 16 (7.8%) had a positive QFT-GIT, and 25 (12.6%) had a 
      positive TSPOT. TST positivity was lower in patients on >/=2 immunosuppressants 
      compared with the controls (5-aminosalicylic acid treatment) (10.4% versus 38.2%, 
      respectively) (P = 0.0057). No other drugs influenced TST or IGRA positivity. In 
      patients on corticosteroid treatment, anti-TNF treatment, or >/=2 
      immunosuppressants, IGRAs detected 10 cases of latent tuberculosis infection not 
      identified by TST. TSPOT and QFT-GIT increased yield by 56% and 22%, 
      respectively. No significant differences in T-cell subpopulations were found 
      between patients with positive or negative TST or TSPOT results. However, 
      patients with positive QFT-GIT findings had more CD8 T cells (mean, 883 +/- 576 
      versus 484 +/- 385 cells per microliter in patients with negative results) (P = 
      0.022). CONCLUSIONS: IGRAs can improve TST-based screening in patients with IBD 
      on immunosuppressive therapy. A low CD8 count can affect QFT-GIT results. We 
      suggest combining TSPOT and TST screening in patients with IBD on 
      immunosuppressants.
FAU - Arias-Guillen, Miguel
AU  - Arias-Guillen M
AD  - *Department of Respiratory Medicine, Instituto Nacional de Silicosis, Hospital 
      Universitario Central de Asturias, Oviedo, Spain; daggerDepartment of Digestive 
      Diseases, Hospital Universitario Central de Asturias, Oviedo, Spain; double daggerDepartment 
      of Microbiology, Mycobacterial Reference Unit, Hospital Universitario Central de 
      Asturias, Oviedo, Spain;  section signDepartment of Respiratory Medicine, Hospital Arnau de 
      Villanova, Valencia, Spain;  ||Division of Pulmonary and Critical Care Medicine and 
      Mayo Clinic Center for Tuberculosis, Mayo Clinic, Rochester, Minnesota; 
       paragraph signDepartment of Radiology, Hospital Universitario Central de Asturias, Oviedo; and 
      **Oficina de Investigacion Biosanitaria, Hospital Universitario Central de 
      Asturias, Oviedo, Spain.
FAU - Riestra, Sabino
AU  - Riestra S
FAU - de Francisco, Ruth
AU  - de Francisco R
FAU - Palacios, Juan Jose
AU  - Palacios JJ
FAU - Belda, Jose
AU  - Belda J
FAU - Escalante, Patricio
AU  - Escalante P
FAU - Perez-Martinez, Isabel
AU  - Perez-Martinez I
FAU - Molinos, Luis M
AU  - Molinos LM
FAU - Garcia-Clemente, Marta
AU  - Garcia-Clemente M
FAU - Pando-Sandoval, Ana
AU  - Pando-Sandoval A
FAU - Rodrigo, Luis
AU  - Rodrigo L
FAU - Prieto, Amador
AU  - Prieto A
FAU - Martinez-Camblor, Pablo
AU  - Martinez-Camblor P
FAU - Losada, Ana
AU  - Losada A
FAU - Casan, Pere
AU  - Casan P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Inflamm Bowel Dis
JT  - Inflammatory bowel diseases
JID - 9508162
SB  - IM
MH  - Adult
MH  - Diagnosis, Differential
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *Immunity, Innate
MH  - Immunologic Tests/methods
MH  - Incidence
MH  - Inflammatory Bowel Diseases/complications/epidemiology/*immunology
MH  - Latent Tuberculosis/complications/*diagnosis/epidemiology
MH  - Lymphocyte Count
MH  - Male
MH  - Mass Screening/*methods
MH  - Middle Aged
MH  - Prevalence
MH  - Prospective Studies
MH  - Risk Factors
MH  - Spain/epidemiology
MH  - T-Lymphocyte Subsets/*immunology
EDAT- 2014/01/01 06:00
MHDA- 2015/01/07 06:00
CRDT- 2014/01/01 06:00
PHST- 2014/01/01 06:00 [entrez]
PHST- 2014/01/01 06:00 [pubmed]
PHST- 2015/01/07 06:00 [medline]
AID - 10.1097/01.MIB.0000438429.38423.62 [doi]
PST - ppublish
SO  - Inflamm Bowel Dis. 2014 Feb;20(2):329-38. doi: 
      10.1097/01.MIB.0000438429.38423.62.